MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway

Gut

Volumn 65, Issue 11, 2016, Pages 1850-1860

  Wu, Heng ^a   Ng, Raymond ^b   Chen, Xin ^c   Steer, Clifford J ^a,d   Song, Guisheng ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b AGENCY FOR SCIENCE   (Singapore)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN D1; LIPID; LIPOPROTEIN; MESSENGER RNA; MICRORNA 21; PROTEIN P53; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; ANTISENSE OLIGONUCLEOTIDE; MICRORNA; MIRN21 MICRORNA, HUMAN; MIRN21 MICRORNA, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CCNB1 GENE; CCND1 GENE; CELL PROLIFERATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE FUNCTION; GENE OVEREXPRESSION; HBP1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID LIVER LEVEL; LIPOGENESIS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN RNA BINDING; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; CARCINOGENESIS; GENE EXPRESSION PROFILING; HEP-G2 CELL LINE; LIPID DIET; LIPID METABOLISM; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; DIET, HIGH-FAT; GENE EXPRESSION PROFILING; HEP G2 CELLS; HUMANS; LIPID METABOLISM; LIVER; LIVER NEOPLASMS; MICE; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIGONUCLEOTIDES, ANTISENSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940195131     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308430     Document Type: Article

References (42)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58.
2. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2003;36:150-5.
3. Calle E, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
4. Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
5. Esquela-Kerscher A, Slack F. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
6. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008;48:1810-20.
7. Gramantieri L, Fornari F, Callegari E, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008;12:2189-204.
8. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
9. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47:1955-63.
10. Ng R, Wu H, Xiao H, et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology 2014;60:554-64.
11. Ahrens M, Ammerpohl O, von Schönfels W, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 2013;18:296-302.
12. Friedman R, Farh K, Burge C, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
13. Krek A, Grün D, Poy M, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
14. Yang J-H, Li J-H, Shao P, et al. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res 2011;39(Suppl 1):D202-9.
15. Harfe BD, McManus MT, Mansfield JH, et al. The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc Natl Acad Sci USA 2005;102:10898-903.
16. Postic C, Magnuson MA. DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 2000;26:149-50.
17. Mattis AN, Song G, Hitchner K, et al. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatology 2014;61:142-51.
18. Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005;79:214-24.
19. Vickers KC, Shoucri BM, Levin MG, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 2013;57:533-42.
20. Cui W, Chen SL, Hu K-Q. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2010;2:95-104.
21. Gomez-Lechon MJ, Donato MT, Martínez-Romero A, et al. A human hepatocellular in vitro model to investigate steatosis. Chem Bio Interact 2007;165:106-16.
22. Li H, Wang W, Liu X, et al. Transcriptional factor HBP1 targets p16INK4A, upregulating its expression and consequently is involved in Ras-induced premature senescence. Oncogene 2010;29:5083-94.
23. Tevosian SG, Shih HH, Mendelson KG, et al. HBP1: a HMG box transcriptional repressor that is targeted by the retinoblastoma family. Genes Dev 1997;11:383-96.
24. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
25. Wang X, Zhao X, Gao X, et al. A new role of p53 in regulating lipid metabolism. J Mol Cell Biol 2013;5:147-50.
26. Yahagi N, Shimano H, Matsuzaka T, et al. p53 involvement in the pathogenesis of fatty liver disease. J Biol Chem 2004;279:20571-5.
27. Edwards PA, Tabor D, Kast HR, et al. Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta 2000;1529:103-13.
28. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31.
29. Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008;34:643-8.
30. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-49.
31. Schupp M, Chen F, Briggs ER, et al. Metabolite and transcriptome analysis during fasting suggest a role for the p53-Ddit4 axis in major metabolic tissues. BMC Genomics 2013;14:758.
32. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013;48:434-41.
33. Bartlett K, Eaton S. Mitochondrial β-oxidation. Eur J Biochem 2004;271:462-9.
34. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-58.
35. Becker P, Niesler B, Tschopp O, et al. MicroRNAs as mediators in the pathogenesis of non-alcoholic fatty liver disease and steatohepatitis. Z Gastroenterol 2014;52:1-27.
36. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009;13:39-53.
37. Ma X, Choudhury SN, Hua X, et al. Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. Carcinogenesis 2013;34:1216-23.
38. Watanabe S, Horie Y, Suzuki A. Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol Res 2005;33:161-6.
39. Castro RE, Ferreira D, Afonso MB, et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 2013;58:119-25.
40. Derdak Z, Villegas KA, Harb R, et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol 2013;58:785-91.
41. Jiang P, Du W, Wang X, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011;13:310-16.
42. Panasiuk A, Dzieciol J, Panasiuk B, et al. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol 2006;12:6198.